Search
Paclitaxel Treatment Options in United Kingdom
A collection of 293 research studies where Paclitaxel is the interventional treatment. These studies are located in the United Kingdom . Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
109 - 120 of 293
A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)
Completed
This is a multi-center, randomized, open-label, phase 1/2 study of continuous weekly paclitaxel and escalating doses of intermittent or continuous OSI-906 in patients with recurrent/relapsed ovarian and other solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Mayo Clinic, Scottsdale, Arizona +45 locations
Conditions: Ovarian Cancer, Solid Tumors
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Completed
The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2024
Locations: Southern Cancer Center, Inc., Mobile, Alabama +289 locations
Conditions: Non-Small Cell Lung Cancer
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Genesis Cancer and Blood Institute (SCRI), Hot Springs, Arkansas +92 locations
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Active Not Recruiting
This is a phase II pilot trial of Paclitaxel Protein Bound and Gemcitabine based chemotherapy and the addition of Paricalcitol upon attainment of stable or progressive disease in eligible patients with untreated metastatic pancreatic ductal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Barts Health NHS Trust, London, London, Greater
Conditions: Pancreatic Cancer
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Active Not Recruiting
This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Instituto Medico Especializado Alexander Fleming, Colegiales, Caba +155 locations
Conditions: Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Completed
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Henry Ford Hospital, Detroit, Michigan +103 locations
Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Terminated
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Mayo Clinic, Phoenix, Arizona +44 locations
Conditions: Triple-Negative Breast Cancer
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Completed
This is a Phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab or placebo in combination with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: St. Joseph's Hospital and Medical Cancer Center, Phoenix, Arizona +89 locations
Conditions: Pancreatic Cancer Non-resectable
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Terminated
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type.
The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Centre Léon Bérard, Dpt Medecine & INSERM, Lyon, Not set +3 locations
Conditions: Metastatic Cancer
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Terminated
The primary objective of the study was to evaluate whether progression-free survival (PFS) was prolonged with the addition of veliparib to standard platinum-based chemotherapy (carboplatin/paclitaxel \[C/P\]) and continued as maintenance therapy compared with chemotherapy alone.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: University of Alabama at Birmingham - Main /ID# 138087, Birmingham, Alabama +209 locations
Conditions: Ovarian Cancer, Ovarian Neoplasm
A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.
Completed
This is a Phase I study to evaluate the safety and toxicity profile of AZD2014, a novel anticancer agent, in combination with paclitaxel.
AZD2014 will be given orally, twice daily at a starting dose of 25 mg per day for 3 days on, 4 days off with a weekly infusion of 80 mg of paclitaxel for 6 weeks followed by a treatment break of one week, therefore each cycle will be 7 weeks long. Cohorts of three patients will be treated at this dose of AZD2014 and then at 50mg and 75 mg providing is it safe... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/24/2024
Locations: Addenbrookes Hospital, Cambridge, Cambridgeshire +3 locations
Conditions: Advanced Cancer
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
Completed
DICE is a randomised study recruiting 126 women over 3 years from hospitals in the UK and Germany. Eligible patients will have tissue based diagnosis of advanced/recurrent ovarian cancer (clear cell, endometrioid or high grade serous or carcinosarcoma), have had chemotherapy before, and be platinum-resistant (the cancer has returned/grown significantly during or within 6 months of platinum-containing chemotherapy).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Charité Universitätsmedizin Berlin, Berlin, Not set +14 locations
Conditions: Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinosarcoma, Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Cancer, Fallopian Tube Neoplasms, Primary Peritoneal Carcinoma, Primary Peritoneal Serous Adenocarcinoma
109 - 120 of 293
